$68.88
3.81[5.86%]
At close: Apr 25
$68.88
0[0.00%]
After Hours: 7:57PM EDT
Viking Therapeutics
(NASDAQ:VKTX)Viking Therapeutics Stock (NASDAQ:VKTX), Analyst Ratings, Price Targets, Predictions
Viking Therapeutics Inc has a consensus price target of $77.69, established from looking at the 48 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Oppenheimer, and Oppenheimer on April 25, 2024, March 27, 2024, and March 26, 2024. With an average price target of $122 between HC Wainwright & Co., Oppenheimer, and Oppenheimer, there's an implied 77.12% upside for Viking Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Oppenheimer
BTIG
Stifel
Maxim Group
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Viking Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/25/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 30.66% | HC Wainwright & Co. | Joseph Pantginis | → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 100.35% | Oppenheimer | Jay Olson | $116 → $138 | Maintains | Outperform | Get Alert |
| 03/26/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 100.35% | Oppenheimer | Jay Olson | $116 → $138 | Maintains | Outperform | Get Alert |
| 03/26/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 81.48% | BTIG | Justin Zelin | $100 → $125 | Maintains | Buy | Get Alert |
| 03/26/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 30.66% | HC Wainwright & Co. | Joseph Pantginis | → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 16.14% | Stifel | Annabel Samimy | → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 45.18% | BTIG | Justin Zelin | $86 → $100 | Maintains | Buy | Get Alert |
| 03/15/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 74.22% | Maxim Group | Naz Rahman | → $120 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 30.66% | HC Wainwright & Co. | Joseph Pantginis | → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 30.66% | HC Wainwright & Co. | Joseph Pantginis | → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 59.7% | Jefferies | Roger Song | → $110 | Initiates | → Buy | Get Alert |
| 02/29/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 74.22% | Truist Securities | Joon Lee | $32 → $120 | Maintains | Buy | Get Alert |
| 02/28/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 68.41% | Oppenheimer | Jay Olson | $46 → $116 | Maintains | Outperform | Get Alert |
| 02/27/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 66.96% | Raymond James | Steven Seedhouse | $37 → $115 | Maintains | Outperform | Get Alert |
| 02/27/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | 30.66% | HC Wainwright & Co. | Joseph Pantginis | $33 → $90 | Maintains | Buy | Get Alert |
| 02/14/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | -49.19% | Stifel | Annabel Samimy | $30 → $35 | Maintains | Buy | Get Alert |
| 02/08/2024 | VKTX | Buy Now | Viking Therapeutics | $68.88 | -27.41% | Maxim Group | Naz Rahman | $35 → $50 | Maintains | Buy | Get Alert |
| 12/04/2023 | VKTX | Buy Now | Viking Therapeutics | $68.88 | -53.54% | Truist Securities | Joon Lee | → $32 | Reiterates | Buy → Buy | Get Alert |
| 10/02/2023 | VKTX | Buy Now | Viking Therapeutics | $68.88 | -53.54% | Truist Securities | Joon Lee | → $32 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Viking Therapeutics (VKTX)?
The latest price target for Viking Therapeutics (NASDAQ: VKTX) was reported by HC Wainwright & Co. on April 25, 2024. The analyst firm set a price target for $90.00 expecting VKTX to rise to within 12 months (a possible 30.66% upside). 31 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Viking Therapeutics (VKTX)?
The latest analyst rating for Viking Therapeutics (NASDAQ: VKTX) was provided by HC Wainwright & Co., and Viking Therapeutics reiterated their buy rating.
When was the last upgrade for Viking Therapeutics (VKTX)?
There is no last upgrade for Viking Therapeutics.
When was the last downgrade for Viking Therapeutics (VKTX)?
The last downgrade for Viking Therapeutics Inc happened on May 25, 2021 when Raymond James changed their price target from $27 to $12 for Viking Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Viking Therapeutics (VKTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viking Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viking Therapeutics was filed on April 25, 2024 so you should expect the next rating to be made available sometime around April 25, 2025.
Is the Analyst Rating Viking Therapeutics (VKTX) correct?
While ratings are subjective and will change, the latest Viking Therapeutics (VKTX) rating was a reiterated with a price target of $0.00 to $90.00. The current price Viking Therapeutics (VKTX) is trading at is $68.88, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.